Immunodominant dengue virus-specific CD8+ T cell responses are associated with a memory PD-1+ phenotype

Journal of Virology

Volumn 90, Issue 9, 2016, Pages 4771-4779

  De Alwis, Ruklanthi ^a   Bangs, Derek J ^a   Angelo, Michael A ^a   Cerpas, Cristhiam ^b   Fernando, Anira ^c   Sidney, John ^a   Peters, Bjoern ^a   Gresh, Lionel ^d   Balmased, Angel ^a,b   De Silva, Aruna D ^a,c   Harris, Eva ^e   Sette, Alessandro ^a   Weiskopf, Daniela ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b Ministerio de Salud   (Nicaragua)

^c Genetech Research Institute   (Sri Lanka)

^d Sustainable Sciences Institute   (Nicaragua)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; EPITOPE; HLA A24 ANTIGEN; HLA ANTIGEN; HLA B35 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; DENGUE; DENGUE VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; NICARAGUA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SRI LANKA; ALLELE; CYTOTOXICITY; GENE EXPRESSION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

ALLELES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENGUE; DENGUE VIRUS; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION; HLA ANTIGENS; HLA-A24 ANTIGEN; HLA-B35 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; NICARAGUA; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS;

EID: 84964963377     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02892-15     Document Type: Article

References (39)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http://dx.doi.org/10.1038/nature12060.
2. Gubler DJ. 1997. Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem, p 1-22. In Gubler DJ, Kuno G (ed), Dengue and dengue hemorrhagic fever. CAB International, New York, NY.
3. Halstead SB. 1979. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140:527-533. http://dx.doi.org/10.1093/infdis/140.4.527.
4. Innis BL. 1997. Antibody responses to dengue virus infection, p 221-243. In Gubler DJ, Kuno G (ed), Dengue and dengue hemorrhagic fever. CAB International, New York, NY.
5. WHO. 2009. Dengue: guidelines for diagnosis, treatment, prevention and control: new edition. WHO, Geneva, Switzerland.
6. Halstead SB, Rojanasuphot S, Sangkawibha N. 1983. Original antigenic sin in dengue. Am J Trop Med Hyg 32:154-156.
7. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB. 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120:653-669.
8. Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak A, Kurane I, Rothman AL, Ennis FA. 1999. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis 180:1429-1435. http://dx.doi.org/10.1086/315072.
9. Rothman AL. 2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11:532-543. http://dx.doi.org/10.1038/nri3014.
10. Chakravarti A, Kumaria R. 2006. Circulating levels of tumour necrosis factor-alpha and interferon-gamma in patients with dengue and dengue haemorrhagic fever during an outbreak. Indian J Med Res 123:25-30.
11. Perez AB, Garcia G, Sierra B, Alvarez M, Vazquez S, Cabrera MV, Rodriguez R, Rosario D, Martinez E, Denny T, Guzman MG. 2004. IL-10 levels in dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol 73:230-234. http://dx.doi.org/10.1002/jmv.20080.
12. + T cells. Proc Natl Acad Sci U S A 110:E2046-E2053. http://dx.doi.org/10.1073/pnas.1305227110.
13. + T cell responses against the four dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis 212:1743-1751. http://dx.doi.org/10.1093/infdis/jiv289.
14. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. 2013. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19:1305-1312. http://dx.doi.org/10.1038/nm.3350.
15. + T cell response. J Immunol 183:7919-7930. http://dx.doi.org/10.4049/jimmunol.0803903.
16. Jin HT, Ahmed R, Okazaki T. 2011. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 350:17-37. http://dx.doi.org/10.1007/82_2010_116.
17. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687. http://dx.doi.org/10.1038/nature04444.
18. + T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 80:3532-3540. http://dx.doi.org/10.1128/JVI.80.7.3532-3540.2006.
19. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354. http://dx.doi.org/10.1038/nature05115.
20. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, Ferrari C. 2006. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 80:11398-11403 http://dx.doi.org/10.1128/JVI.01177-06.
21. Hokey DA, Johnson FB, Smith J, Weber JL, Yan J, Hirao L, Boyer JD, Lewis MG, Makedonas G, Betts MR, Weiner DB. 2008. Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol 38:1435-1445. http://dx.doi.org/10.1002/eji.200737857.
22. Fernandez RJ, Vazquez S. 1990. Serological diagnosis of dengue by an ELISA inhibition method (EIM). Mem Inst Oswaldo Cruz 85:347-351. http://dx.doi.org/10.1590/S0074-02761990000300012.
23. Harris E, Videa E, Perez L, Sandoval E, Tellez Y, Perez ML, Cuadra R, Rocha J, Idiaquez W, Alonso RE, Delgado MA, Campo LA, Acevedo F, Gonzalez A, Amador JJ, Balmaseda A. 2000. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua.AmJ Trop Med Hyg 63:5-11.
24. de Alwis R, de Silva AM. 2014. Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique. Methods Mol Biol 1138:27-39. http://dx.doi.org/10.1007/978-1-4939-0348-1_3.
25. Sette A, Sidney J. 1999. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 50:201-212. http://dx.doi.org/10.1007/s002510050594.
26. + T-cell response to lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an old virus. J Virol 81:4928-4940. http://dx.doi.org/10.1128/JVI.02632-06.
27. Sidney J, Peters B, Frahm N, Brander C, Sette A. 2008. HLA class I supertypes: a revised and updated classification. BMC Immunol 9:1. http://dx.doi.org/10.1186/1471-2172-9-1.
28. Appanna R, Ponnampalavanar S, Lum Chai See L, Sekaran SD. 2010. Susceptible and protective HLA class 1 alleles against dengue fever and dengue hemorrhagic fever patients in a Malaysian population. PLoS One 5:e13029. http://dx.doi.org/10.1371/journal.pone.0013029.
29. Falcon-Lezama JA, Ramos C, Zuniga J, Juarez-Palma L, Rangel-Flores H, Garcia-Trejo AR, Acunha-Alonzo V, Granados J, Vargas-Alarcon G. 2009. HLA class I and II polymorphisms in Mexican Mestizo patients with dengue fever. Acta Trop 112:193-197. http://dx.doi.org/10.1016/j.actatropica.2009.07.025.
30. Nguyen TP, Kikuchi M, Vu TQ, Do QH, Tran TT, Vo DT, Ha MT, Vo VT, Cao TP, Tran VD, Oyama T, Morita K, Yasunami M, Hirayama K. 2008. Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLAA* 24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl Trop Dis 2:e304. http://dx.doi.org/10.1371/journal.pntd.0000304.
31. Wherry EJ. 2011. T cell exhaustion. Nat Immunol 12:492-499.
32. Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, Rufer N, Matter M, Michielin O, Speiser DE. 2012. Extended coexpression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 7:e30852. http://dx.doi.org/10.1371/journal.pone.0030852.
33. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. 2013. Inhibitory receptor expression depends more dominantly on differentiation and activation than "exhaustion" of human CD8 T cells. Front Immunol 4:455. http://dx.doi.org/10.3389/fimmu.2013.00455.
34. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 187:1395-1402. http://dx.doi.org/10.1084/jem.187.9.1395.
35. + T cells. J Immunol 182:4865-4873. http://dx.doi.org/10.4049/jimmunol.0801974.
36. + T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol 193:4117-4124. http://dx.doi.org/10.4049/jimmunol.1401597.
37. + T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J Virol 89:6494-6505. http://dx.doi.org/10.1128/JVI.00036-15.
38. Brown KE, Freeman GJ, Wherry EJ, Sharpe AH. 2010. Role of PD-1 in regulating acute infections. Curr Opin Immunol 22:397-401. http://dx.doi.org/10.1016/j.coi.2010.03.007.
39. + T cells. J Exp Med 212:1125-1137. http://dx.doi.org/10.1084/jem.20142237.